Log in

Relevant bibliographies by topics / Phospholipid antibodies / Journal articles

To see the other types of publications on this topic, follow the link: Phospholipid antibodies.

Journal articles on the topic 'Phospholipid antibodies'

Author: Grafiati

Published: 4 June 2021

Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Phospholipid antibodies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Out, HJ, PG de Groot, M. van Vliet, GC de Gast, HK Nieuwenhuis, and RH Derksen. "Antibodies to platelets in patients with anti-phospholipid antibodies." Blood 77, no. 12 (June 15, 1991): 2655–59. http://dx.doi.org/10.1182/blood.v77.12.2655.2655.

Full text

Abstract:

Abstract Binding of anti-phospholipid antibodies to circulating platelets and its consequences on platelet activation and aggregation was investigated in 11 patients with anti-phospholipid antibodies. Seven patients had mild thrombocytopenia. Nine healthy donors served as controls. Binding to platelets was investigated by performing enzyme- linked immunosorbent assays (ELISAs) with phospholipids as antigen on platelet eluates. Platelet activation was measured by flow cytofluorometry using monoclonal antibodies to an activation-specific lysosomal membrane protein. Findings in ELISA were compare

APA, Harvard, Vancouver, ISO, and other styles

2

Out, HJ, PG de Groot, M. van Vliet, GC de Gast, HK Nieuwenhuis, and RH Derksen. "Antibodies to platelets in patients with anti-phospholipid antibodies." Blood 77, no. 12 (June 15, 1991): 2655–59. http://dx.doi.org/10.1182/blood.v77.12.2655.bloodjournal77122655.

Full text

Abstract:

Binding of anti-phospholipid antibodies to circulating platelets and its consequences on platelet activation and aggregation was investigated in 11 patients with anti-phospholipid antibodies. Seven patients had mild thrombocytopenia. Nine healthy donors served as controls. Binding to platelets was investigated by performing enzyme- linked immunosorbent assays (ELISAs) with phospholipids as antigen on platelet eluates. Platelet activation was measured by flow cytofluorometry using monoclonal antibodies to an activation-specific lysosomal membrane protein. Findings in ELISA were compared with re

APA, Harvard, Vancouver, ISO, and other styles

3

Rauch, J., and AS Janoff. "Antibodies against Phospholipids other than Cardiolipin: Potential Roles for Both Phospholipid and Protein." Lupus 5, no. 5 (October 1996): 498–502. http://dx.doi.org/10.1177/096120339600500534.

Full text

Abstract:

Autoantibodies to phospholipids other than cardiolipin have received less attention, to date, than anti-cardiolipin antibodies. This review focuses on these antibodies and potential roles for both phospholipid and protein in their reactivity. We review data in the literature indicating that antibodies to phosphatidylethanolamine and some lupus anticoagulant antibodies recognize phospholipid-binding proteins in association with phospholipid. Kininogens appear to be involved in the binding of antibodies to phosphatidylethanolamine, while phosphatidylserine-binding proteins, such as prothrombin a

APA, Harvard, Vancouver, ISO, and other styles

4

Harris, EN, and SS Pierangeli. "Functional Effects of Anticardiolipin Antibodies." Lupus 5, no. 5 (October 1996): 372–77. http://dx.doi.org/10.1177/096120339600500507.

Full text

Abstract:

The ‘lupus anticoagulant’ phenomenon is the best documented functional effect of antiphospholipid (aPL) antibodies, occurring either by inhibition of the prothrombinase and/or Factor X activation reactions. Understanding the mechanism by which aPL antibodies inhibit phospholipid dependent coagulation reactions may yield important clues about their ‘thrombogenic effects’ in vivo. We conducted a series of studies to determine the specificity, diversity, and mechanism by which aPL antibodies inhibit phospholipid dependent reactions. Results showed that purified immunoglobulins with lupus anticoag

APA, Harvard, Vancouver, ISO, and other styles

5

BRIGHTON, Timothy A., Yan-Ping DAI, Philip J. HOGG, and Colin N. CHESTERMAN. "Microheterogeneity of beta-2 glycoprotein I: implications for binding to anionic phospholipids." Biochemical Journal 340, no. 1 (May 10, 1999): 59–67. http://dx.doi.org/10.1042/bj3400059.

Full text

Abstract:

Considerable interest is currently focused on the interactions of beta-2 glycoprotein I (β2GPI) and anti-phospholipid antibodies with anionic phospholipids in an attempt to understand the association between these antibodies and clinical diseases such as thrombosis. The interactions of β2GPI and anionic phospholipids have only been characterized partially, and the physiological role of this glycoprotein remains uncertain. In this study we have explored in detail the physical and phospholipid-binding characteristics of a number of β2GPI preparations. We have found (i) that perchloric acid-purif

APA, Harvard, Vancouver, ISO, and other styles

6

Harris, E. N., A. E. Gharavi, and G. R. V. Hughes. "Anti-phospholipid Antibodies." Clinics in Rheumatic Diseases 11, no. 3 (December 1985): 591–609. http://dx.doi.org/10.1016/s0307-742x(21)00606-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Tincani, A., L. Andreoli, and Y. Shoenfeld. "Anti-phospholipid antibodies." Rheumatology 53, no. 2 (November 27, 2013): 201–2. http://dx.doi.org/10.1093/rheumatology/ket394.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Deegan, Michael J. "Anti-Phospholipid Antibodies." American Journal of Clinical Pathology 98, no. 4 (October 1, 1992): 390–91. http://dx.doi.org/10.1093/ajcp/98.4.390.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Mackworth-Young, C. G. "Anti phospholipid antibodies." Current Opinion in Immunology 1, no. 4 (January 1988): 747–52. http://dx.doi.org/10.1016/0952-7915(89)90052-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Banerji, Benoy, and Carl R. Alving. "Antibodies to liposomal phosphatidylserine and phosphatidic acid." Biochemistry and Cell Biology 68, no. 1 (January 1, 1990): 96–101. http://dx.doi.org/10.1139/o90-012.

Full text

Abstract:

Polyclonal antisera to phosphatidylserine or phosphatidic acid were induced in rabbits by injecting liposomes containing phosphatidylserine or phosphatidic acid and lipid A. Adsorption of antisera with liposomes containing different phospholipids revealed that some degree of reactivity with one or more phospholipids other than the immunizing phospholipid was often observed. However, cross-reactivity with other phospholipids was not a universal phenomenon, and one antiserum to phosphatidylserine failed to cross-react (i.e., was not adsorbed) with liposomes containing other phospholipids. All of

APA, Harvard, Vancouver, ISO, and other styles

11

Salemink, Irene, Ron Blezer, George Willems, Monica Galli, Edouard Bevers та Theo Lindhout. "Antibodies to β2-Glycoprotein I Associated with Antiphospholipid Syndrome Suppress the Inhibitory Activity of Tissue Factor Pathway Inhibitor". Thrombosis and Haemostasis 84, № 10 (2000): 653–56. http://dx.doi.org/10.1055/s-0037-1614082.

Full text

Abstract:

SummaryAnionic phospholipid membranes have a dual role in blood coagulation: they are essential for the initiation and propagation as well as for the limitation and termination of the blood coagulation process. Patients with the anti-phospholipid syndrome (APS) carrying antibodies against complexes of anionic phospholipids and plasma proteins, show in vitro inhibited phospholipid dependent coagulation reactions, whereas in vivo the presence of these antibodies is associated with an increased risk of thrombosis. In this study we focussed on the effects of these anti-phospholipid antibodies on t

APA, Harvard, Vancouver, ISO, and other styles

12

Oort, Erica van, Mariëlle Tempelman, Ronald Derksen, Philip de Groot та Daniëlle Horbach. "The Prevalence of a Non-phospholipid-binding Form of β2-Glycoprotein I in Human Plasma". Thrombosis and Haemostasis 80, № 11 (1998): 791–97. http://dx.doi.org/10.1055/s-0037-1615360.

Full text

Abstract:

SummaryThe presence of antiphospholipid antibodies (aPL) is strongly correlated with venous and arterial thrombosis, fetal loss and thrombocytopenia. This relation is called the antiphospholipid syndrome (APS). It is well recognized that thrombosis related aPL are not directed against phospholipids alone, but to phospholipid bound plasma proteins like β2-glycoprotein I (β2GPI). aPL that need β2GPI for the binding to negatively charged phospholipids are called anti-β2GPI-antibodies. Recently, a mutation in the gene encoding β2GPI has been described, which results in an amino acid substitution T

APA, Harvard, Vancouver, ISO, and other styles

13

Pengo, V., A. Biasiolo, T. Brocco, S. Tonetto, and A. Ruffatti. "Autoantibodies to Phospholipid-binding Plasma Proteins in Patients with Thrombosis and Phospholipid-reactive Antibodies." Thrombosis and Haemostasis 75, no. 05 (1996): 721–24. http://dx.doi.org/10.1055/s-0038-1650355.

Full text

Abstract:

SummaryAnti-phospholipid (aPL) antibodies are defined as antibodies detected in systems employing phospholipids (PL). This general definition is misleading as it comprises a large group of autoimmune phospholipid-reactive antibodies that are directed against specific phospholipid-binding plasma proteins, such as β2-glycoprotein I (β2GPI) and prothrombin. Definition of phospholipid-reacting antibodies according to the plasma protein against which they are directed appears more appropriate and could be useful in understanding clinical events and pathogenic mechanisms. Using ELISA systems we have

APA, Harvard, Vancouver, ISO, and other styles

14

Wu, X. X., and J. H. Rand. "Antiphospholipid antibody-mediated interference with annexin-V anticoagulant activity." Hämostaseologie 21, no. 02 (2001): 50–53. http://dx.doi.org/10.1055/s-0037-1619508.

Full text

Abstract:

SummaryThe antiphospholipid (aPL) syndrome is a disorder in which vascular thrombosis and/or recurrent pregnancy losses occur together with serologic and coagulation evidence for antibodies directed against anionic phospholipid-protein complexes. Evidence has been developed for the idea that thrombosis in this syndrome may result from disruption of the binding of annexin-V to the phospholipids which line the placental and systemic vasculatures. We hypothesize that annexin-V, a protein known to have high affinity for anionic phospholipids, plays a thromboregulatory role at the vascular-blood in

APA, Harvard, Vancouver, ISO, and other styles

15

Panarelli, P., M. P. Viola-Magni, and E. Albi. "Antiphosphatidylinositol Antibody in Deep Venous Thrombosis Patients." International Journal of Immunopathology and Pharmacology 16, no. 1 (January 2003): 61–66. http://dx.doi.org/10.1177/039463200301600109.

Full text

Abstract:

Antiphospholipid antibodies are a heterogeneous group of immunoglobulins with specificity for a number of phospholipids, phospholipid-binding proteins and phospholipid-protein complexes. The association between antiphospholipid antibodies and a variety of pathologic disorders, such as arterial and venous thrombosis and recurrent pregnancy loss is recognized as Antiphospholipid Syndrome. The immunoassay currently used to detect antiphospholipid antibodies is the anticardiolipin test. Anticardiolipin antibodies are believed to be polyspecific antibodies that cross-react with all the anionic phos

APA, Harvard, Vancouver, ISO, and other styles

16

Reddy, Ketha Ravindra, and V. S. Sai Lakshmi. "An Association between Anti-Phospholipid Antibodies and Connective Tissue Diseases." Asian Journal of Medical Research 8, no. 3 (September 2019): DT01—DT03. http://dx.doi.org/10.21276/ajmr.2019.8.3.dt1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Kouts, S., M. X. Wang, S. Adelstein, and S. A. Krilis. "Immunization of a rabbit with beta 2-glycoprotein I induces charge-dependent crossreactive antibodies that bind anionic phospholipids and have similar reactivity as autoimmune anti-phospholipid antibodies." Journal of Immunology 155, no. 2 (July 15, 1995): 958–66. http://dx.doi.org/10.4049/jimmunol.155.2.958.

Full text

Abstract:

Abstract A rabbit immunized with beta 2-glycoprotein I (beta 2-GPI) produced Abs that bind to negatively charged phospholipids and to beta 2-GPI. After affinity purification of the Abs to beta 2-GPI, the dual reactivity could still be detected. Adsorption studies with a phosphatidylserine affinity column depleted phospholipid-reactive Abs, but beta 2-GPI reactivity was retained. The same pattern of reactivity was found with culture supernatants from rabbit anti-beta 2-GPI splenocytes fused with an immortalized rabbit cell line. The reactivity to negatively charged phospholipids is likely to in

APA, Harvard, Vancouver, ISO, and other styles

18

Wu, Xiao-Xuan, and Jacob Rand. "Antibody-Mediated Disruption of the Annexin-V Antithrombotic Shield: A New Mechanism for Thrombosis in the Antiphospholipid Syndrome." Thrombosis and Haemostasis 82, no. 08 (1999): 649–55. http://dx.doi.org/10.1055/s-0037-1615892.

Full text

Abstract:

IntroductionThe antiphospholipid (aPL) syndrome is a condition that manifests in patients as vascular thromboembolism or recurrent pregnancy loss together with laboratory evidence for the presence of antibodies against anionic phospholipid-protein complexes. For a recent comprehensive review, the reader is referred to Hughes et al.1 The syndrome was first proposed to be a distinct entity, called anticardiolipin syndrome, in 1985,2 and was later renamed antiphospholipid syndrome.3 The disorder was classified as “primary” in the absence of a concurrent autoimmune condition, such as systemic lupu

APA, Harvard, Vancouver, ISO, and other styles

19

Sanmarco, M., and M.-C. Boffa. "Antiphosphatidylethanolamine antibodies and the antiphospholipid syndrome." Lupus 18, no. 10 (August 11, 2009): 920–23. http://dx.doi.org/10.1177/0961203309106920.

Full text

Abstract:

The antiphospholipid antibodies included as laboratory criteria of the antiphospholipid syndrome (APS) are antibodies reacting with anionic phospholipids – anticardiolipin antibodies and lupus anticoagulant – and with β2-glycoprotein I. However, antibodies reacting with phosphatidylethanolamine (aPE), a zwitterionic phospholipid, have also been described to be associated with the main features of APS. The objectives of this review are to describe the characteristics of aPE and to bring attention to recent evidence that aPE are correlated with the main clinical features of APS, notably, in the

APA, Harvard, Vancouver, ISO, and other styles

20

Ernst, J. D. "Epitope mapping of annexin I: antibodies that compete with phospholipids and calcium recognize amino acids 42–99." Biochemical Journal 289, no. 2 (January 15, 1993): 539–42. http://dx.doi.org/10.1042/bj2890539.

Full text

Abstract:

To understand further the structural basis of phospholipid binding by annexin I, three monoclonal antibodies that compete with Ca2+ and phospholipids for binding of annexin I were used to screen an expression library containing fragments of bovine annexin I cDNA. In all, 15 clones were isolated, and all contain overlapping fragments of the cDNA. The smallest unit common to all of the clones encodes amino acids 42-99 of annexin I, representing a portion of the first repeat domain. This demonstrates that recognition of a single domain of annexin I is sufficient to completely block phospholipid b

APA, Harvard, Vancouver, ISO, and other styles

21

Shuaib, Ashfaq, Lynn Barklay, Mary Anne Lee, and Oksana Suchowersky. "Migraine and Anti-Phospholipid Antibodies." Headache: The Journal of Head and Face Pain 29, no. 1 (January 1989): 42–45. http://dx.doi.org/10.1111/j.1526-4610.1989.hed2901042.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Carp, H. J. A., and Y. Shoenfeld. "Anti-Phospholipid Antibodies And Infertility." Clinical Reviews in Allergy & Immunology 32, no. 2 (June 30, 2007): 159–61. http://dx.doi.org/10.1007/s12016-007-0010-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

NORBERG, RENÉE, J. ERNERUDH, A. HAMSTEN, A. M. UNANDER, and L. ÅRFORS. "Phospholipid Antibodies in Cardiovascular Disease." Acta Medica Scandinavica 221, S715 (April 24, 2009): 93–98. http://dx.doi.org/10.1111/j.0954-6820.1987.tb09908.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Helbert, M., S. Bodger, J. Cavenagh, D. D'Cruz, J. M. Thomas, and P. MacCallum. "Optimising testing for phospholipid antibodies." Journal of Clinical Pathology 54, no. 9 (September 1, 2001): 693–98. http://dx.doi.org/10.1136/jcp.54.9.693.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Mesa, H. A., B. Lang, M. Schumacher, P. Vaith, and H. H. Peter. "Sneddon's syndrome and phospholipid antibodies." Clinical Rheumatology 12, no. 2 (June 1993): 253–56. http://dx.doi.org/10.1007/bf02231537.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Galli, M. "Phospholipid inhibitors." Hämostaseologie 31, no. 04 (2011): 243–50. http://dx.doi.org/10.5482/ha-1165.

Full text

Abstract:

SummaryThe antiphospholipid syndrome (APS) is defined by the association of arterial and/or venous thrombosis and/or pregnancy complications with the presence of at least one among the main antiphospholipid antibodies (aPL) (i. e., Lupus anticoagulants, LA, IgG and/ or IgM anticardiolipin antibodies, aCL, IgG and/or IgM antiβ2-glycoprotein I antibodies, aβ2-GPI). Several clinical studies have consistently reported that LA is a stronger risk factor for both arterial and venous thrombosis compared to aCL and aβ2-GPI. In particular, LA activity dependent on the first domain of β2-GPI and triple a

APA, Harvard, Vancouver, ISO, and other styles

27

Stewart, M. W., W. S. Etches, A. S. Russell, J. S. Percy, C. A. Johnston, C. K. Chew, and P. A. Gordon. "Detection of Antiphospholipid Antibodies by Flow Cytometry: Rapid Detection of Antibody Isotype and Phospholipid Specificity." Thrombosis and Haemostasis 70, no. 04 (1993): 603–7. http://dx.doi.org/10.1055/s-0038-1649636.

Full text

Abstract:

SummaryLaboratory diagnosis of antiphospholipid antibodies is important in patients with clinical features of the antiphospholipid syndrome, such as thrombosis and fetal loss. We have developed a novel method for the detection of antiphospholipid antibodies using flow cytometry. Anionic phospholipids cardiolipin, phosphatidylserine and phosphatidylinositol are coated onto polystyrene beads of different sizes, allowing detection and semiquantitation of their respective phospholipid antibody isotypes. The results of the flow cytometric method closely correlate those of the standardised anticardi

APA, Harvard, Vancouver, ISO, and other styles

28

Rauch, J. "Lupus anticoagulant antibodies: Recognition of phospholipid-binding protein complexes." Lupus 7, no. 2_suppl (February 1998): 29–31. http://dx.doi.org/10.1177/096120339800700207.

Full text

Abstract:

Lupus anticoagulant antibodies form a heterogeneous group of antiphospholipid antibodies with rather poorly defined antigens. The role that phospholipid-binding proteins play in lupus anticoagulant antibody activity is a subject of current investigation. Several candidate proteins have been proposed, including β2-glycoprotein I (β2GPI), prothrombin, and annexin V. As β2GPI-dependent lupus anticoagulants will be reviewed elsewhere in this issue, this paper will focus on the involvement of prothrombin and annexin V in lupus anticoagulant activity. Evidence for a role for these proteins in the re

APA, Harvard, Vancouver, ISO, and other styles

29

Maltseva, L. I., and L. A. Lobova. "Clinical importance of antiphospholipid antibodies in pregnants with mycoplasma and associated infection." Kazan medical journal 82, no. 2 (April 3, 2001): 107–10. http://dx.doi.org/10.17816/kazmj66606.

Full text

Abstract:

The examination of 167 infected pregnants in I and II terms was carried out to reveal the rate of antiphospholi pid antibodies in pregnants with mycoplasma and associated infection. The pathologic level of anti phospholipid antibodies was determined in 21% of the pregnants with micoplasma and associated infection, in 22% of them the anti phospholipid syndrome was revealed. The most severe complications of pregnancy and accompanied extragenital pathology were found in women with anti phospholipid antibodies. During complex therapy the elimination of antibodies accompanying by the positive clini

APA, Harvard, Vancouver, ISO, and other styles

30

Misasi, Roberta, Antonella Capozzi, Agostina Longo, Serena Recalchi, Emanuela Lococo, Cristiano Alessandri, Fabrizio Conti, Guido Valesini, and Maurizio Sorice. "“New” Antigenic Targets and Methodological Approaches for Refining Laboratory Diagnosis of Antiphospholipid Syndrome." Journal of Immunology Research 2015 (2015): 1–13. http://dx.doi.org/10.1155/2015/858542.

Full text

Abstract:

Antiphospholipid antibodies (aPLs) are a heterogeneous group of antibodies directed against phospholipids or protein/phospholipid complexes. Currently, aPLs are assessed using either “solid-phase” assays that identify anticardiolipin antibodies and anti-β2-glycoprotein I antibodies or “liquid-phase” assay that identifies lupus anticoagulant. However, in the last few years, “new” antigenic targets and methodological approaches have been employed for refining laboratory diagnosis of antiphospholipid syndrome (APS). In this review the potential diagnostic value of antibodies to domains ofβ2-GPI,

APA, Harvard, Vancouver, ISO, and other styles

31

Shapoorabadi, Farzaneh Ahmadi, Maryam Sadat Mirbagheri Firoozabad, Neda Habibi, and Giti Emtiazi. "Hemolysis, Platelet Aggregation and Antibacterial Activities of Human Antiphospholipid Antibody." Anti-Infective Agents 18, no. 3 (September 11, 2020): 268–74. http://dx.doi.org/10.2174/2211352517666190613111628.

Full text

Abstract:

Background: Anti-phospholipid antibodies have the potential to become an alternative to conventional antibiotics for humans. The Antiphospholipid Syndrome (APS) is an autoimmune disease where the body’s defense system incorrectly reacts against its own phospholipids. APS is distinct through the existence of venous and arterial thromboses, frequently multiple and recurring fetal losses, commonly accompanied by moderate thrombocytopenia. Anti-phospholipid antibodies include lupus anti-coagulant, anti- cardiolipin, anti-beta 2 glycoprotein 1, and anti-prothrombin antibodies. Methods: In this stud

APA, Harvard, Vancouver, ISO, and other styles

32

Hu, Yanqing, Charles T. Esmon, and Naomi L. Esmon. "Function of Beta2-GPI in Inhibiting the Oxidized Phospholipids Dependent APC Activity by Antiphospholipid IgG from APS Patients." Blood 108, no. 11 (November 16, 2006): 1612. http://dx.doi.org/10.1182/blood.v108.11.1612.1612.

Full text

Abstract:

Abstract Beta2-GPI (ß2GPI), a plasma glycoprotein with phospholipid-binding properties, is the actual target antigen for autoimmune type antiphospholipid antibodies. Certain groups of these antibodies exert lupus anticoagulant (LA) activity by directly inhibiting the Protein C anticoagulant pathway and associated with an increased risk of thrombotic disease. Our previous studies have shown that the activated protein C (APC) activity and the ability to be inhibited by antiphospholipid antibodies associated with thrombosis are strongly augmented by the presence of Phosphatidyl-ethanolamine (PE)

APA, Harvard, Vancouver, ISO, and other styles

33

Aleman, Maria M., Siddharth Jindal, Nina Leksa, Robert Peters, and Joe Salas. "Phospholipid-Independent Activity of Fviiia Mimetic Bispecific Antibodies in Plasma." Blood 132, Supplement 1 (November 29, 2018): 2461. http://dx.doi.org/10.1182/blood-2018-99-119226.

Full text

Abstract:

Abstract Introduction: An important coagulation regulatory mechanism is localization of clotting complexes to exposed phosphatidylserine (PS) on cell surfaces. All components of the intrinsic tenase complex (factor (F)VIIIa, FIXa, and FX) bind to PS. FVIIIa mimetic bispecific antibodies are drugs in development for hemophilia A that aim to mimic the cofactor function of FVIIIa by bringing together FIXa and FX to generate FXa. However, these antibodies differ from FVIII in many ways including no requirement of activation and a lack of direct PS binding. Emicizumab is a bispecific antibody curre

APA, Harvard, Vancouver, ISO, and other styles

34

Petri, M. "Update on anti-phospholipid antibodies in SLE: the Hopkins’ Lupus Cohort." Lupus 19, no. 4 (March 30, 2010): 419–23. http://dx.doi.org/10.1177/0961203309360541.

Full text

Abstract:

Anti-phospholipid antibodies are common in patients in the Hopkins’ Lupus Cohort: 47% have anti-cardiolipin, 32.5% anti-β2-glycoprotein I and 26% lupus anticoagulant (by dRVVT confirmatory testing). Systemic lupus erythematosus patients with the lupus anticoagulant at baseline have a 50% chance of a deep venous thrombosis/pulmonary embolus in the next 20 years. Anti-phospholipid antibodies differ in their association with thrombosis: the lupus anticoagulant is most strongly associated with arterial and venous thrombosis and is the only anti-phospholipid antibody associated with myocardial infa

APA, Harvard, Vancouver, ISO, and other styles

35

Amiral, Jean. "Diagnostic Approach of Phospholipid-Dependent Antibodies." Pathophysiology of Haemostasis and Thrombosis 29, no. 2-3 (1999): 135–49. http://dx.doi.org/10.1159/000022494.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Carreras, L. O., and R. R. Forastiero. "Pathogenic Role Of Antiprotein-Phospholipid Antibodies." Pathophysiology of Haemostasis and Thrombosis 26, no. 4 (1996): 340–57. http://dx.doi.org/10.1159/000217316.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Kilpatrick, D. C. "ANTI-PHOSPHOLIPID ANTIBODIES AND PREGNANCY WASTAGE." Lancet 328, no. 8513 (October 1986): 980–81. http://dx.doi.org/10.1016/s0140-6736(86)90633-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Out, Henk Jan, Hein W. Bruinse, and Ronald H. W. M. Derksen. "Anti-phospholipid antibodies and pregnancy loss." Human Reproduction 6, no. 6 (July 1991): 889–97. http://dx.doi.org/10.1093/oxfordjournals.humrep.a137446.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Chedid, Antonio, Kurmanadha R. Chadalawada, Timothy R. Morgan, Thomas E. Moritz, Charles L. Mendenhall, James B. Hammond, Peter W. Emblad, et al. "Phospholipid antibodies in alcoholic liver disease." Hepatology 20, no. 6 (December 1994): 1465–71. http://dx.doi.org/10.1002/hep.1840200614.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Brandt, John T. "Antibodies to β2-Glycoprotein I Inhibit Phospholipid Dependent Coagulation Reactions". Thrombosis and Haemostasis 70, № 04 (1993): 598–602. http://dx.doi.org/10.1055/s-0038-1649635.

Full text

Abstract:

SummaryLupus anticoagulants are antibodies that inhibit phospholipid dependent coagulation reactions in vitro. These antibodies are of clinical interest because of their association with a variety of clinical manifestations characterized by microvascular thrombosis. Although these antibodies were originally thought to be directed at negatively charged phospholipid, recent studies have suggested that they may be directed at phospholipid-protein complexes. The effect of antibodies directed against β2-glycoprotein I (β2-GP I, apolipoprotein H) on phospholipid-dependent coagulation reactions has b

APA, Harvard, Vancouver, ISO, and other styles

41

Galli, M., G. Finazzi, EM Bevers, and T. Barbui. "Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and beta 2-glycoprotein I-dependent antiphospholipid antibodies." Blood 86, no. 2 (July 15, 1995): 617–23. http://dx.doi.org/10.1182/blood.v86.2.617.bloodjournal862617.

Full text

Abstract:

Antiphospholipid (aPL) antibodies include anticardiolipin (aCL) and lupus anticoagulant (LA) antibodies. LA antibodies recognize the complex of lipid-bound (human) prothrombin, in this way inhibiting the phospholipid-dependent coagulation reactions, whereas aCL antibodies are directed towards beta 2-glycoprotein I (beta 2-GPI) bound to an anionic lipid surface. According to their behavior in coagulation reactions, we have divided aCL antibodies into two groups: aCL-type A, which inhibit the phospholipid-dependent coagulation reactions because they enhance the binding of beta 2-GPI to the proco

APA, Harvard, Vancouver, ISO, and other styles

42

Umeda, M., K. Igarashi, K. S. Nam, and K. Inoue. "Effective production of monoclonal antibodies against phosphatidylserine: stereo-specific recognition of phosphatidylserine by monoclonal antibody." Journal of Immunology 143, no. 7 (October 1, 1989): 2273–79. http://dx.doi.org/10.4049/jimmunol.143.7.2273.

Full text

Abstract:

Abstract A system based on the direct immunization of phospholipid Ag into mouse spleen has been used to produce mAb against phosphatidylserine (PS). mAb that bind to PS but not to phosphatidylcholine were selected. Remarkable frequency of the production of mAb against PS was observed with the immunization protocol. The mAb exhibited three distinct reactivity profiles ranging from highly specific to broadly cross-reactive. Among 61 hybridomas, 15 mAb were established for further analysis. The reactivities of three typical mAb, designated PS4A7, PS3A, and PSC8, are described. PS4A7 is highly sp

APA, Harvard, Vancouver, ISO, and other styles

43

Rand, Jacob H., Xiao-Xuan Wu, Harry A. M. Andree, J. B. Alexander Ross, Elena Rusinova, Mayra G. Gascon-Lema, Cesare Calandri, and Peter C. Harpel. "Antiphospholipid Antibodies Accelerate Plasma Coagulation by Inhibiting Annexin-V Binding to Phospholipids: A “Lupus Procoagulant” Phenomenon." Blood 92, no. 5 (September 1, 1998): 1652–60. http://dx.doi.org/10.1182/blood.v92.5.1652.

Full text

Abstract:

Abstract The antiphospholipid syndrome is a thrombophilic condition marked by antibodies that recognize anionic phospholipid-protein cofactor complexes. We recently reported that exposure to IgG fractions from antiphospholipid patients reduces the level of annexin-V, a phospholipid-binding anticoagulant protein, on cultured trophoblasts and endothelial cells and accelerates coagulation of plasma exposed to these cells. Therefore, we asked whether antiphospholipid antibodies might directly reduce annexin-V binding to noncellular phospholipid substrates. Using ellipsometry, we found that antipho

APA, Harvard, Vancouver, ISO, and other styles

44

Rand, Jacob H., Xiao-Xuan Wu, Harry A. M. Andree, J. B. Alexander Ross, Elena Rusinova, Mayra G. Gascon-Lema, Cesare Calandri, and Peter C. Harpel. "Antiphospholipid Antibodies Accelerate Plasma Coagulation by Inhibiting Annexin-V Binding to Phospholipids: A “Lupus Procoagulant” Phenomenon." Blood 92, no. 5 (September 1, 1998): 1652–60. http://dx.doi.org/10.1182/blood.v92.5.1652.417k21_1652_1660.

Full text

Abstract:

The antiphospholipid syndrome is a thrombophilic condition marked by antibodies that recognize anionic phospholipid-protein cofactor complexes. We recently reported that exposure to IgG fractions from antiphospholipid patients reduces the level of annexin-V, a phospholipid-binding anticoagulant protein, on cultured trophoblasts and endothelial cells and accelerates coagulation of plasma exposed to these cells. Therefore, we asked whether antiphospholipid antibodies might directly reduce annexin-V binding to noncellular phospholipid substrates. Using ellipsometry, we found that antiphospholipid

APA, Harvard, Vancouver, ISO, and other styles

45

Rand, JH, X.-X. Wu, AS Quinn, and DJ Taatjes. "The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis." Lupus 19, no. 4 (March 30, 2010): 460–69. http://dx.doi.org/10.1177/0961203310361485.

Full text

Abstract:

Annexin A5 (AnxA5) binds to phospholipid bilayers, forming two-dimensional crystals that block the phospholipids from availability for coagulation enzyme reactions. Antiphospholipid (aPL) antibodies cause gaps in the ordered crystallization of AnxA5 which expose phospholipids and thereby accelerate blood coagulation reactions. The aPL antibody-mediated disruption of AnxA5 crystallization has been confirmed on artificial phospholipid bilayers and on cell membranes including endothelial cells, placental trophoblasts and platelets. Recently, we reported that hydroxychloroquine, a synthetic antima

APA, Harvard, Vancouver, ISO, and other styles

46

Gharavi, Azzudin E., Silvia S. Pierangeli, Margaret Colden-Stanfield, Xiao Wei Liu, Ricardo G. Espinola, and E. Nigel Harris. "GDKV-Induced Antiphospholipid Antibodies Enhance Thrombosis and Activate Endothelial Cells In Vivo and In Vitro." Journal of Immunology 163, no. 5 (September 1, 1999): 2922–27. http://dx.doi.org/10.4049/jimmunol.163.5.2922.

Full text

Abstract:

Abstract Antiphospholipid (aPL) Abs are associated with thrombosis, pregnancy loss, and thrombocytopenia in patients with systemic lupus erythematosus or primary antiphospholipid syndrome (APS). β2-Glycoprotein I (β2GPI), a phospholipid-binding serum protein, is involved in aPL binding to phospholipids. aPL can be generated in mice by immunization with β2GPI, and these Abs are thrombogenic and cause pregnancy loss in mice. The objective of this study is to determine whether aPL induced by immunization with the phospholipid-binding site of β2GPI are thrombogenic and whether they activate endoth

APA, Harvard, Vancouver, ISO, and other styles

47

Baidoun, Firas, Rommy Issa, Robert Ali, and Bashar Al-Turk. "Acute Unilateral Blindness from Superior Ophthalmic Vein Thrombosis: A Rare Presentation of Nephrotic Syndrome from Class IV Lupus Nephritis in the Absence of Antiphospholipid or Anticardiolipin Syndrome." Case Reports in Hematology 2015 (2015): 1–3. http://dx.doi.org/10.1155/2015/413975.

Full text

Abstract:

Patients with systemic lupus erythematosus (SLE) are at high risk of arterial and venous thrombosis secondary to anti-phospholipid antibodies. Herein, we are presenting an interesting case of venous thrombosis in a patient with SLE in the absence of anti-phospholipid antibodies.

APA, Harvard, Vancouver, ISO, and other styles

48

Sorice, M., P. Arcieri, T. Griggi, A. Circella, R. Misasi, L. Lenti, G. D. Di Nucci, and G. Mariani. "Inhibition of Protein S by Autoantibodies in Patients with Acquired Protein S Deficiency." Thrombosis and Haemostasis 75, no. 04 (1996): 555–59. http://dx.doi.org/10.1055/s-0038-1650320.

Full text

Abstract:

SummaryThis study was undertaken to analyze antibodies to protein S (PS) in patients with an acquired PS deficiency. Plasma from symptomatic patients with acquired (n = 14) or congenital (n = 10) PS deficiency and 10 healthy donors was screened for PS antibodies by immunoblotting and for anti-phospholipid antibodies. PS antibodies (IgG) were detected in five of the patients with acquired PS deficiency. These antibodies belonged to the G1 and G4 immunoglobulin subclasses. IgG fractions from the same 5 patients were shown to inhibit PS activity. The inhibition of PS activity by the 5 IgG fractio

APA, Harvard, Vancouver, ISO, and other styles

49

Bizzaro, Nicola, Elio Tonutti, Danilo Villalta, Marilina Tampoia, and Renato Tozzoli. "Prevalence and Clinical Correlation of Anti-Phospholipid–Binding Protein Antibodies in Anticardiolipin-Negative Patients With Systemic Lupus Erythematosus and Women With Unexplained Recurrent Miscarriages." Archives of Pathology & Laboratory Medicine 129, no. 1 (January 1, 2005): 61–68. http://dx.doi.org/10.5858/2005-129-61-paccoa.

Full text

Abstract:

Abstract Context.—Anti-phospholipid antibodies (aPL) are a heterogeneous group of autoantibodies, the presence of which is associated with thrombotic events and miscarriage. Objective.—To establish whether antibodies directed against phospholipid-binding plasma proteins such as β2-glycoprotein I (β2GPI), prothrombin (PT), and annexin V (Anx V) constitute a risk factor for thromboembolism in patients with systemic lupus erythematosus (SLE) and for miscarriage in women with recurrent pregnancy loss (RPL), independently of the presence of the classic anticardiolipin (aCL) antibodies, and whether

APA, Harvard, Vancouver, ISO, and other styles

50

Shi, W., BH Chong, and CN Chesterman. "Beta 2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants." Blood 81, no. 5 (March 1, 1993): 1255–62. http://dx.doi.org/10.1182/blood.v81.5.1255.1255.

Full text

Abstract:

Abstract Antiphospholipid (aPL) antibodies are of major interest not only because the lupus anticoagulant (LA) causes an inhibition of in vitro blood coagulation, but also because the presence of aPL antibodies confers a risk of thrombosis. The inhibition of in vitro phospholipid- dependent coagulation (LA) is thought to be caused by the binding of LA to procoagulant phospholipid surfaces, thus impeding the clotting process. Another class of aPL antibodies are those originally described to be directed against negatively charged phospholipids, in particular cardiolipin (ACA). ACA are usually di

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!